Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Selective inhibitors of DYRK1A are of interest for the treatment of cancer, Type 2 diabetes and neurological disorders. Optimization of imidazo [1,2-b]pyridazine fragment 1 through structure-activity relationship exploration and in silico drug design efforts led to the discovery of compound 17 as a potent cellular inhibitor of DYRK1A with selectivity over much of the kinome. The binding mode of compound 17 was elucidated with X-ray crystallography, facilitating the rational design of compound 29, an imidazo [1,2-b]pyridazine with improved kinase selectivity with respect to closely related CLK kinases.

Original publication

DOI

10.1016/j.ejmech.2024.116292

Type

Journal article

Journal

European journal of medicinal chemistry

Publication Date

04/2024

Volume

269

Addresses

Sussex Drug Discovery Centre, University of Sussex, Brighton, BN1 9RH, UK. Electronic address: scott.henderson@benevolent.ai.

Keywords

Humans, Diabetes Mellitus, Type 2, Iohexol, Pyridazines, Protein Kinase Inhibitors, Structure-Activity Relationship, Dyrk Kinases